The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: BioMS

Monday Biotech Deal Review: July 12, 2010

This week saw several interesting deals, including an $85+ million exit for Sentinelle, some “bio-bucks” made good for Cipher, a licensing deal for Amorfix’s vCJD technology, a $10 million malaria deal for BC-based Artepharm and a new name (Medwell Capital) to go along with BioMS’ new business model. Read more of this post

Monday Biotech Deal Review: May 10, 2010

Some people were on the move this week — not only did Sanofi Canada announce 70 R&D job cuts, but BioMS took on a new banker and Labopharm, CardioComm and GeneNews all get new faces. Despite the fact that it seemed half of the country’s companies and deal-makers were at BIO in Chicago this week, there was still a fair amount of positive deal activity including numerous private placements, commercial agreements and a bit of M&Eh.

Read more of this post

Monday Biotech Deal Review: May 3, 2010

I guess the excitement of BIO was driving deals this week. To the delight of the economic development folks, government was in on the action — Ontario announced a BIP investment and announced a whole new strategy, and OICR funded three equity deals. The private sector was also out in force, with four new licensing deals (including some interesting structures) and more securities than the week might otherwise … warrant. Keep reading after the jump…

Monday Biotech Deal Review: March 8, 2010

A busy week in Canadian deals, with Paladin Labs in a global transaction with SpePharm; M&A activity from therapeutics and consulting companies; the last of the SIFT/SR&ED deals; over $20 million of new offerings from BioSign, Bradmer and YM; government funding for Medicago and Isotechnika; a new standby equity deal from Yorkville for Allon; and the closing of the first deal of the rest of BioMS’ new life. Read more of this post

Monday Biotech Deal Review: February 15, 2010

A busy Monday Deal Review is headlined by Labopharm and ProMetric on the securities front, MDS’ final divestiture on the M&Eh front and Biovail and Bioniche on the licensing front, and there’s lots more activity behind those for over $100 million of deals.  Check out all the details (and the witty headlines) after the jump…

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis and Chattem and Seattle Genetics and GSK.  Check out the past week’s Canadian deal-making (and breaking) after the jump…

BioMS’ New Directions — Buys 48% of Spectral Diagnostics, Still Has Dry Powder

BioMS (TSE: MS), which like the kids in Glee* was in need of some re-invention, has entered a new phase.  BioMS announced that it is investing $11.7 million in Spectral Diagnostics (TSE: SDI), which will use the funds to advance its lead product Toraymyxin, a treatment for severe sepsis.  Spectral will pay BioMS $3 million over the next 3 years for clinical, regulatory and capital markets consulting services.

Is this a one-time deal, or the beginning of a shopping spree? Shares of BioMS, which had about $53 million in cash left at the end of September, were up about 7% today.

If you’re done with the idle speculation and ready for the terms of the financing, (which is subject to TSX and Spectral shareholder approval) Read more of this post

BioMS and Lilly Terminate Dirucotide Agreement

Not surprising, given the failure of the SPMS trial (etc.) in July, but Eli Lilly and BioMS have terminated their license and collaboration agreement, with “all commercial rights to dirucotide … returned to BioMS.”  No indication from the press release where BioMS is headed, just that they’re “completing [their] review of the additional dirucotide clinical data and assessing the strategic options available.”  Sigh.

Bookmark and Share

Monday Deal Review: March 9, 2009

A big dose of Canadian deals and company info from this week after the jump…

Trends in 2009: You’ve Got a Friend In…

story yesterday reminded me about a movement I think we’ll start seeing a lot more of — funding to commercial entities by disease advocacy foundations.  This will be fueled in 2009 by two factors:

  • a self-perpetuating availability heuristic that will encourage foundations to seek commercialization opportunities; and
  • an economic environment that will have companies looking harder than ever for non-dilutive financing.

Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 129 other followers